新长效β2-受体激动剂三氟甲磺酸维兰特罗

摘要

Vilanterol trifenatate is a novel inhaled long-actingβ2-agonist with inherent 24 h activity. Compared with salmeterol, vilanterol trifenatate has a faster onset and longer duration of action. It showed a good safety proifle and was generally well tolerated in subjects with asthma and chronic obstructive pulmonary disease (COPD). The once-daily dosing regimen could help improve compliance and represent a promising advance in the treatment of asthma and COPD.%　　三氟甲磺酸维兰特罗是一个经口吸入的长效选择性β2-受体激动剂，可持续作用24 h。与沙美特罗相比，三氟甲磺酸维兰特罗起效更快、持续作用时间更长，在哮喘和慢性阻塞性肺病患者中的安全性和耐受性良好，一日1次的给药方案还可以改善患者的依从性，为哮喘和慢性阻塞性肺病患者提供了新的治疗选择。